SkinBioTherapeutics PLC operates as a life science company that focuses on skin health. Its SkinBiotix platform could enhance the barrier effect of skin models, improve repair, and reduce bacterial load. The company intends to serves skin healthcare sectors in cosmetics, infection control, and eczema. The company is based in Macclesfield, the United Kingdom. SkinBioTherapeutics PLC is a subsidiary of OptiBiotix Health plc.
Industry, Sector and Symbol
Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:SBTX
CUSIPN/A
Phone+44-161-4682760
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-16.85%
Return on Assets-16.40%
Miscellaneous
EmployeesN/A
Outstanding Shares118,710,000
Market Cap£11.01
Skinbiotherapeutics (LON:SBTX) Frequently Asked Questions
What is Skinbiotherapeutics' stock symbol?
Skinbiotherapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SBTX."
What is the consensus analysts' recommendation for Skinbiotherapeutics?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Skinbiotherapeutics in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Who are some of Skinbiotherapeutics' key competitors?
Some companies that are related to Skinbiotherapeutics include Realm Therapeutics (RLM), Ceapro (CZO), Nuvo Pharmaceuticals (NRI), Concordia International (CXR), Netscientific (NSCI), Acasti Pharma (ACST), Actinium Pharmaceuticals (ATNM), Kalytera Therapeutics (KALTF), CAN-FITE BIOPHA/S (CANF), biOasis Technologies (BTI), Factor Therapeutics (FTT), Prana Biotechnology (PBT), ReNeuron Group (RENE), Pediapharm (PDP) and Ibio (IBIO).
Who are Skinbiotherapeutics' key executives?
Skinbiotherapeutics' management team includes the folowing people:
- Dr. Catherine O'Neill, CEO & Director
- Mr. Douglas John Quinn, CFO, Company Sec. & Director
- Mr. Mark Kingsley Collingbourne, Sec. (Age 52)
Has Skinbiotherapeutics been receiving favorable news coverage?
News articles about SBTX stock have trended somewhat negative this week, Accern reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Skinbiotherapeutics earned a news impact score of -0.10 on Accern's scale. They also gave news articles about the company an impact score of 45.02 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Skinbiotherapeutics?
Shares of SBTX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Skinbiotherapeutics' stock price today?
One share of SBTX stock can currently be purchased for approximately GBX 16.
How big of a company is Skinbiotherapeutics?
Skinbiotherapeutics has a market capitalization of £11.01 million.
How can I contact Skinbiotherapeutics?
Skinbiotherapeutics' mailing address is 15 1 Silk House, Park Green, MACCLESFIELD, SK11 7QJ, United Kingdom. The company can be reached via phone at +44-161-4682760.
MarketBeat Community Rating for Skinbiotherapeutics (LON SBTX)
MarketBeat's community ratings are surveys of what our community members think about Skinbiotherapeutics and other stocks. Vote "Outperform" if you believe SBTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
